Filing Details
- Accession Number:
- 0001127602-17-026845
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-09-01 18:15:34
- Reporting Period:
- 2017-08-30
- Accepted Time:
- 2017-09-01 17:15:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1334682 | H Gregg Alton | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Evp Comm&Acs Ala, Corp&Med Aff | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-08-30 | 22,124 | $24.91 | 113,237 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2017-08-30 | 21,001 | $26.99 | 134,238 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-08-30 | 50,000 | $79.00 | 84,238 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2017-08-30 | 22,124 | $0.00 | 22,124 | $24.91 |
| Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2017-08-30 | 21,001 | $0.00 | 21,001 | $26.99 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 67,876 | 2019-07-29 | No | 4 | M | Direct | |
| 0 | 2018-07-30 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
Billionaire Hedge Funds
